Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

Fig. 1

Pharmacokinetic analysis of ONC201. a ONC201 plasma concentrations following the first dose of cycle 1 and cycle 2. Concentrations are shown as the mean for each dose cohort in dose escalation (375 mg and 625 mg). b Cmax and AUC for 375 mg (n = 3) and 625 mg (n = 17) dose cohorts for cycle 1 and cycle 2. Each error bar indicates SEM

Back to article page